ExcelMale
Menu
Home
What's new
Latest activity
Forums
New posts
Search forums
What's new
New posts
Latest activity
Videos
Lab Tests
Doctor Finder
Buy Books
About Us
Men’s Health Coaching
Log in
Register
What's new
Search
Search
Search titles only
By:
New posts
Search forums
Menu
Log in
Register
Navigation
Install the app
Install
More options
Contact us
Close Menu
Forums
ExcelFemale
HRT in Women
Evaluating brexanolone for the treatment of PostPartum Depression
JavaScript is disabled. For a better experience, please enable JavaScript in your browser before proceeding.
You are using an out of date browser. It may not display this or other websites correctly.
You should upgrade or use an
alternative browser
.
Reply to thread
Message
<blockquote data-quote="madman" data-source="post: 202528" data-attributes="member: 13851"><p><strong>Article highlights</strong></p><p></p><p>● <em><strong>Postpartum depression is a serious complication of pregnancy with significant morbidity and mortality.</strong> </em></p><p></p><p>● <em><strong>Brexanolone is the first pharmacologic agent specifically approved for the treatment of postpartum depression. </strong></em></p><p></p><p>● <strong><em><u>Brexanolone can be thought of as a synthetic version of the neurosteroid allopregnanolone which acts as a positive allosteric modulator of the gamma-aminobutyric acid, A receptor thus regulating the major inhibitory neurotransmitter in the brain</u>.</em></strong></p><p></p><p>● <strong><em>Brexanolone is given as a 3-day intravenous infusion and requires continuous pulse oximetry monitoring.</em></strong></p><p></p><p>● <strong><em>Brexanolone reduces postpartum depression symptoms within hours of administration, results in remission in a large portion of patients, and has sustained effects for at least 30 days after infusion.</em></strong></p><p></p><p>● <strong><em>Brexanolone with its novel mechanism of action and its rapid, significant, and sustained response is an exciting breakthrough agent for psychiatry.</em></strong></p></blockquote><p></p>
[QUOTE="madman, post: 202528, member: 13851"] [B]Article highlights[/B] ● [I][B]Postpartum depression is a serious complication of pregnancy with significant morbidity and mortality.[/B] [/I] ● [I][B]Brexanolone is the first pharmacologic agent specifically approved for the treatment of postpartum depression. [/B][/I] ● [B][I][U]Brexanolone can be thought of as a synthetic version of the neurosteroid allopregnanolone which acts as a positive allosteric modulator of the gamma-aminobutyric acid, A receptor thus regulating the major inhibitory neurotransmitter in the brain[/U].[/I][/B] ● [B][I]Brexanolone is given as a 3-day intravenous infusion and requires continuous pulse oximetry monitoring.[/I][/B] ● [B][I]Brexanolone reduces postpartum depression symptoms within hours of administration, results in remission in a large portion of patients, and has sustained effects for at least 30 days after infusion.[/I][/B] ● [B][I]Brexanolone with its novel mechanism of action and its rapid, significant, and sustained response is an exciting breakthrough agent for psychiatry.[/I][/B] [/QUOTE]
Insert quotes…
Verification
Post reply
Share this page
Facebook
Twitter
Reddit
Pinterest
Tumblr
WhatsApp
Email
Share
Link
Sponsors
Forums
ExcelFemale
HRT in Women
Evaluating brexanolone for the treatment of PostPartum Depression
This site uses cookies to help personalise content, tailor your experience and to keep you logged in if you register.
By continuing to use this site, you are consenting to our use of cookies.
Accept
Learn more…
Top